Clinical studies with MTA. (Q33503458)

27 July 2017

6 references

3 April 2019

17 September 2019

19 November 2019

14 September 2020

3 December 2020

8 February 2021

Clinical studies with MTA. (English)

1 reference

27 July 2017

1 reference

3 April 2019

heterocyclic compound

1 reference

17 September 2019

1 reference

19 November 2019

1 reference

14 September 2020

1 reference

3 December 2020

1 reference

8 February 2021

Calvert AH

1

1 reference

27 July 2017

Walling JM

series ordinal

2

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

British Journal of Cancer

27 July 2017

published in

7 references

27 July 2017

3 April 2019

17 September 2019

19 November 2019

14 September 2020

3 December 2020

8 February 2021

78 Suppl 3

1 reference

27 July 2017

page(s)

35-40

1 reference

Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer

27 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062802

Intrinsic and acquired resistance to methotrexate in acute leukemia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062802

The pharmacology and clinical use of methotrexate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062802

A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062802

Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062802

Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062802

Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062802

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2062802

Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance

21 June 2018

1 reference

12 December 2020

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes

1 reference

12 December 2020

Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer

1 reference

12 December 2020

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

1 reference

12 December 2020

Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase

1 reference

12 December 2020

Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer

1 reference

12 December 2020

Practical modifications of the continual reassessment method for phase I cancer clinical trials

1 reference

12 December 2020

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.752

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference